Teclistamab, a human bispecific antibody targeting both BCMA on target cells and CD3 on T cells, facilitates T cell-mediated cytotoxicity, which results in T cell activation and subsequent target cell lysis. This compound has applications in research studies concerning multiple myeloma (MM) [1].